STRO — Sutro Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $92.80m
- -$224.10m
- $62.04m
Annual balance sheet for Sutro Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 368 | 198 | 334 | 376 | 317 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.56 | 12.5 | 7.12 | 36.1 | 8.62 |
| Prepaid Expenses | |||||
| Total Current Assets | 378 | 219 | 353 | 422 | 343 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 12.9 | 51.6 | 51.1 | 44.8 | 35.9 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 394 | 341 | 407 | 471 | 387 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29.6 | 41.7 | 66.5 | 93.7 | 132 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 62.1 | 88.8 | 190 | 321 | 343 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 332 | 253 | 217 | 150 | 44.6 |
| Total Liabilities & Shareholders' Equity | 394 | 341 | 407 | 471 | 387 |
| Total Common Shares Outstanding |